Found "Pharmaceuticals": 23 results
Sort by
A - Z

A Determination of Topics for Health Technology Assessment in Thailand: Case Study for Decision Makers Participation (2007-2008) (in Thai language)

An aim of this study is to describe quantitatively and qualitatively progression and findings from the HTA topic selection process recently developed by HITAP. The process involves potential users of HTA information; namely (1) third party payers (public health insurers), (2) national health care program managers (Ministry of Public Health’s Depa

Achillion hepatitis C drug shows promise in mid-stage study

The company said the drug sovaprevir, when given along with the standard therapy of pegylated interferon and ribavirin, showed no detectable virus level in a majority of patients four weeks after the end of the treatment period.Of the 39 patients who received 12 weeks of additional standard therapy

After Delay, OxyContin’s Use in Young Is Under Study

To learn how best to prescribe powerful drugs to children, Congress passed a law in the 1990s that rewarded drug makers for conducting clinical studies involving children. Among the incentives for cooperating companies was a possible six-month extension of protection from generic competition after a

Assessing the implications of Thailand’s government use licenses, issued in 2006-2008

This study aims to assess the impact of the compulsory licensing (CL ) policy issued by Thailand’s Ministry of Public Health during December 2006 to January 2008 on antiretroviral drugs - efavirenz and lopinavir/ritonavir combination, an oral antiplatelet agent - clopidogrel, and four anti-cancer drugs - imatinib, erlotinib, letrozole, and doceta

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. (2013)

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T

California county wants drug makers to pay for pill disposal

(Reuters) – Pharmaceutical companies selling drugs in parts of the San Francisco Bay area would be required to submit plans for incinerating or safely disposing of unused medication under a plan advanced by county officials this week.The measure, billed by supporters as the first of its kind in the

Designing a decision frame for making health resource allocation decisions: a case study in Thailand

The abundance of various innovations in healthcare (pharmaceuticals, medical devices, interventions, individual and community health promotion and disease prevention as well as a social health policy) have been continuously used in the healthcare system, resulting in a higher demand for resources and budgets in disease prevention and healthcare. Th

Development of health technology assessment management

The Health Intervention and Technology Assessment Program (HITAP) was established in 2007 as a non-profit organization. Its main responsibility is to assess health interventions and technology assessment with the coverage of pharmaceuticals, medical devices, interventions, individual and community health promotions and disease prevention, as well a

Drug Maker Seeks Protection Within Bill Favoring Generics

WASHINGTON — One of the few bills moving through Congress with bipartisan support this spring would speed government approval of lower-cost generic copies of brand-name drugs. But one company, with help from an influential former congressman, is lobbying to protect its most lucrative brand-name prod

Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients in the Thai healthcare system

The Thai healthcare system faces pressure to fund high-cost new branded pharmaceuticals. Paying more may encourage innovation with positive implications for future population health, but it also means less money is available to fund other healthcare with negative implications for current population health. Recent work in the UK estimated, for the f
10 / Page